Long-term treatment with sodium warfarin results in decreased femoral bone strength and cancellous bone volume in rats

Thrombosis Research

Volumn 105, Issue 4, 2002, Pages 353-358

  Simon, Ryan R ^a   Beaudin, Suzanne M ^a   Johnston, Marilyn ^a   Walton, Kimberly J ^a   Shaughnessy, Stephen G ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b HAMILTON HEALTH SCIENCES   (Canada)

Author keywords

Anticoagulants; Bone; Osteoporosis; Warfarin

Indexed keywords

SODIUM CHLORIDE; WARFARIN; ANTICOAGULANT AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOMECHANICS; BONE STRENGTH; CANCELLOUS BONE; CELL SURFACE; CONTROLLED STUDY; FEMUR; LONG TERM CARE; MORPHOMETRICS; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOID; PRIORITY JOURNAL; PROTHROMBIN TIME; RANDOMIZATION; RAT; ANIMAL; BONE DENSITY; BONE REMODELING; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; HUMAN; OSTEOPOROSIS; PATHOLOGY; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT; TIME;

ANIMAL; ANTICOAGULANTS; BIOMECHANICS; BONE DENSITY; BONE REMODELING; FEMUR; HUMAN; OSTEOBLASTS; OSTEOCLASTS; OSTEOPOROSIS; RATS; RATS, SPRAGUE-DAWLEY; SUPPORT, NON-U.S. GOV'T; TIME FACTORS; WARFARIN; ANIMALS; HUMANS;

EID: 0037082374     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(02)00035-X     Document Type: Article

References (36)

1. Warfarin therapy: A review of the literature since the fifth American college of chest physicians' consensus conference on antithrombotic therapy
2. Oral anticoagulant drugs
3. Hemorrhagic complications of long-term anticoagulant therapy
4. Major bleeding in outpatients treated with warfarin: Incidence and prediction by factors known at the start of outpatient therapy
5. Warfarin necrosis of the skin and subcutaneous tissue of the male genitalia
6. Maternal and fetal sequelae of anticoagulation during pregnancy
7. Reduced bone mineral content in patients taking an oral anticoagulant
8. Decreased peripheral bone mineral content in patients under anticoagulant therapy with phenprocoumon
9. Heparins, coumarin, and bone density
10. Decreased axial and peripheral bone density in patients taking long-term warfarin
11. Long-term oral anticoagulation reduces bone mass in patients with previous hemispheric infarction and nonrheumatic atrial fibrillation
12. Long-term use of oral anticoagulants and the risk of fracture
13. Normal cortical bone mass in patients after long term coumadin therapy
14. Taux d'osteocalcine et masse osseuse chez les patients recevant des antivitamines K
15. Vitamin K and maintenance of skeletal integrity in adults
16. Warfarin use and risk for osteoporosis in elderly women
17. Bone strength: The bottom line
18. Biomechanics of bone
19. A histomorphometric comparison of the effects of heparin and low molecular-weight heparin on cancellous bone in rats
20. A histomorphometric evaluation of heparin-induced bone loss after discontinuation of heparin treatment in rats
21. Dexamethasone effects on mechanical, geometric and densiometric properties of rat femur diaphysis as described by peripheral quantitative computerized tomography and bending tests
22. Growth hormone is not able to counteract osteopenia of rat cortical bone induced by glucocorticoid with protracted effect
23. Oral anticoagulants: Mechanism of action, clinical effectiveness, and optimal therapeutic range
24. Consensus guidelines for warfarin therapy
25. Role of vitamin K and gla proteins in the pathophysiology of osteoporosis and vascular calcification
26. The vitamin K-dependent proteins: An update
27. Skeletal functions of vitamin K-dependent proteins: Not just for clotting any more
28. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein
29. Increased bone formation in osteocalcin-deficient mice
30. Effects of warfarin on bone. Studies on the vitamin K-dependent protein of rat bone
31. Concurrent warfarin treatment further reduces bone mineral levels in 1,25-dihydroxyvitamin D3-treated rats
32. Excessive mineralization with growth plate closure in rats on chronic warfarin treatment
33. The effect of vitamin K supplimentation on circulating osteocalcin (bone gla protein) and urinary calcium excretion
34. Vitamin K-induced changes in, markers for osteoblast activity and urinary calcium loss
35. Similarities and differences between the effects of ipriflavone and vitamin k on bone resorption and formation in vitro
36. Pharmacological interventions for the prevention of vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: Does site-specificity exist?